LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence company, today reported continued advancement of its mobile healthcare application ecosystem, including applications being prepared for anticipated availability through the Apple App Store and Google Play Store. The company also announced it has surpassed 1,000 early-stage platform subscribers, a milestone management believes reflects growing engagement with its healthcare technology platform.
The applications under development are designed to support telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare initiatives as part of the company's broader digital healthcare infrastructure strategy. Management stated that development, testing, integration, and platform optimization efforts are ongoing for multiple mobile applications intended to improve healthcare accessibility in emerging markets, particularly Latin America.
According to the company, certain applications are being prepared for submission to the Apple App Store and Google Play Store following continued development, internal testing, platform review, and regulatory considerations. No assurance can be provided regarding the timing of any public release or commercial availability.
Dr. Kevin Rodan Levy, CEO of LataMed AI, said: “We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives.”
The company believes continued subscriber onboarding and user engagement will provide valuable operational feedback as development progresses and additional platform functionality is evaluated. LataMed AI's technology initiatives remain focused on scalable healthcare infrastructure solutions for underserved markets where access to healthcare coordination and digital tools is limited.
For more information, visit https://latamed.ai or review the company's SEC filings at www.sec.gov.
